StockData
Biogen Inc. logo

Biogen Inc. (BIIB) KPIs and segments

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$251.41+0.62 (+0.25%)

Close on Nov 18, 2026Market cap $37.16BP/E 107.4Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Biogen · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026)

Nhìn nhanh KPI của Biogen: 56 chỉ số vận hành, trong đó có Growth Portfolio Revenue, Total Consolidated Revenue và Total Product Revenue, Net, lấy từ 139 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Product revenue, net($M)2
2,0891,9161,7521,6671,8471,8791,7271,8331,7691,9001,7121,832
U. S.($M)
1,2651,115839918935941754832813847746848
Rest of World($M)
8248029137509129389731,0019561,053966984
MS Product Revenues($M)2
9199639589171,0621,1079531,0701,0541,1501,0761,168
U. S.($M)
584621559582643657490559546582503621
Rest of World($M)
335342398335419450463511508567573547
Rare Disease Product Revenue($M)2
676602557515533543563535495534424472
U. S.($M)
354295225265235235231244240238226217
Rest of World($M)
322307333249298308332291254297198255
Revenue from anti-CD20 therapeutic programs($M)
497514419494467378446445394
SPINRAZA($M)2
461402374356374393424421381429341413
U. S.($M)
246204142169153149154167153157149158
Rest of World($M)
214198232188221243270255228272193255
TYSABRI($M)2
437451442398432455382415406462431465
U. S.($M)
253271242245248272201230228249214248
Rest of World($M)
184180200153184182181185179214218217
Royalty Attributed To OCREVUS($M)
370381317386386354289354347336303338
Fumarate($M)2
274287289293383406345404391418382401
U. S.($M)
198204185193234235157195175188150203
Rest of World($M)
76.18310499.5149171188210216230232197
Specialized Immunology($M)2
24312800
U. S.($M)
24312800
Rest of World($M)
0000
Interferon($M)2
208225228226247247226236238251244280
U. S.($M)
133146133144161150133134144145140170
Rest of World($M)
757994.781.885.796.793.610294106104110
VUMERITY($M)2
192197179181215212139177158166128156
U. S.($M)
167172153157190188117154135144106140
Rest of World($M)
25.324.525.624.62524.321.72323.221.621.616.9
SYFOVRE($M)2
19197.400
U. S.($M)
19197.400
Rest of World($M)
0000
SKYCLARYS($M)2
1781681511331331301241021021007855.9
U. S.($M)
97.282.371.888.974.67869.170.781.875.67355.9
Rest of World($M)
8185.678.944.558.352.354.831.520.524.450
Biosimilars($M)2
166153182170197182181202197198197188
Rest of World($M)
166153182165195179177197192187193180
U. S.($M)
00.1004.9022.504.3054.3011.13.707.90
AVONEX($M)2
157170163163189178167170176183179206
U. S.($M)
110121109119133122109107116117111140
Rest of World($M)
46.649.154.743.355.15658.262.760.665.667.366.6
Contract manufacturing, royalty and other revenue($M)
150242247151245293232109182
Contract manufacturing revenue($M)
13623223730.6142225282118222100152105
BENEPALI($M)2
117107122108122112111125118117119108
Rest of World($M)
117107122108122112111125118117119108
U. S.($M)
000000000000
Other($M)2
84.470.855.455.346.829.424.117.615.2
U. S.($M)
83.470.755.355.346.428.122.315.713.3
Rest of World($M)
10.100.1000.401.301.801.901.90
ZURZUVAE($M)2
84.470.855.465.755.346.427.722.92214.912.41.60
U. S.($M)
83.470.755.365.755.346.427.722.92214.912.41.60
Rest of World($M)
10.100.10000000000
TECFIDERA($M)2
8290.9110112168194206228233252254244
Rest of World($M)
50.858.578.174.9124146166187193208211181
U. S.($M)
31.232.431.436.944.647.239.841.340.144.143.763.8
Alzheimer's collaboration revenue($M)
68.463.759.542.754.93318.611.82.80
Alzheimer's Collaboration($M)
68.463.759.547.142.754.93326.718.611.82.80
PLEGRIDY($M)2
51.655.164.363.258.46959.56661.368.165.173.9
Rest of World($M)
28.429.94038.530.640.735.439.333.439.936.543.1
U. S.($M)
23.225.224.324.727.828.324.126.727.928.228.630.8
EMPAVELI($M)2
51.530.400
U. S.($M)
51.530.40
Rest of World($M)
000
IMRALDI($M)2
4237.849.643.552.646.747.45154.153.254.854.5
Rest of World($M)
4237.849.643.552.646.747.45154.153.254.854.5
U. S.($M)
000000000000
QALSODY($M)2
37.531.932.52526.42015.511.711.154.603.30
Rest of World($M)
26.723.62217.219.112.585.305.600.400.200
U. S.($M)
10.88.3010.57.807.307.507.506.405.504.604.403.30
Royalty and other revenue($M)
13.8109.7013.29.7019.61112.29.70929.612.8
FLIXABI($M)2
6.408.1010.59.9015.314.313.116.116.213.117.816.7
Rest of World($M)
6.408.1010.59.9015.314.313.116.116.213.117.816.7
U. S.($M)
000000000000
BYOOVIZ($M)2
0.200.1007.9078.608.909.30813.75.609.20
Rest of World($M)
0.20003.6056.104.704.403.903.401.901.30
U. S.($M)
00.1004.3022.504.204.904.1010.33.707.90
FAMPYRA($M)2
0001.10000.3014.419.418.719.223
U. S.($M)
000000000000
Rest of World($M)
0001.10000.3014.419.418.719.223
FUMADERM And ADUHELM($M)2
000000.401.702.702.102.702.802.40
Rest of World($M)
000000.401.301.901.801.901.901.90
U. S.($M)
0000000.400.800.300.800.900.50
TOFIDENCE($M)2
0000.60000.100.100.200.8000
Rest of World($M)
000000000000
U. S.($M)
0000.60000.100.100.200.8000
Growth Portfolio Revenue($M)1
1,2601,060851
Growth Portfolio Revenue Growth YoY(%)
49.0%24.0%12.0%6.0%
Total Consolidated Revenue($M)3
2,8042,7362,4782,2792,5352,6462,4312,4552,4662,4652,2912,386
Reported Revenue Growth YoY(%)
10.6%3.4%1.9%-7.1%2.8%7.3%6.1%2.9%-2.5%0.4%-7.0%-6.2%
Constant-Currency Revenue Growth YoY(%)
10.2%1.6%-1.6%-7.2%1.9%7.5%7.6%2.4%-2.8%0.9%-7.0%-4.9%
Foreign Exchange & Hedging Impact (pp)(%)
0.4%1.8%3.5%0.1%0.9%-0.2%-1.5%0.5%0.3%-0.5%0.0%-1.3%
Total Product Revenue, Net($M)3
2,0891,9161,7521,6671,8471,8791,7271,8331,7691,9001,7121,832
Reported Revenue Growth YoY(%)
13.1%2.0%1.5%-9.0%4.4%-1.1%0.9%0.0%-2.0%4.7%-2.9%-3.8%
Constant-Currency Revenue Growth YoY(%)
12.5%0.0%-2.5%-9.3%3.2%-0.8%2.5%-0.4%-2.2%5.6%-2.6%-2.0%
Foreign Exchange & Hedging Impact (pp)(%)
0.6%2.0%4.0%0.3%1.2%-0.3%-1.6%0.4%0.2%-0.9%-0.3%-1.8%
Revenue from Anti-CD20 Therapeutic Programs($M)5
497514419521494467378465446445394436
Share of U.S. Pre-Tax Profits — RITUXAN, GAZYVA & LUNSUMIO($M)
11812694.712810110883.710794.810387.194.4
Other Revenue from Anti-CD20 Programs($M)
9.106.407.207.506.505.805.704.804.604.804.203.40
Reported Revenue Growth YoY(%)
0.7%9.9%10.8%12.0%10.7%5.1%-4.0%6.7%6.0%2.6%
Constant-Currency Revenue Growth YoY(%)
0.7%9.8%10.7%12.0%10.7%5.1%-4.0%6.7%6.0%2.5%
Foreign Exchange & Hedging Impact (pp)(%)
0.0%0.1%0.1%0.0%0.0%0.0%0.0%0.0%0.0%0.1%
Alzheimer's Collaboration Revenue (Biogen 50% Net Share)($M)3
68.463.759.547.142.754.93326.718.611.82.801.60
Reported Revenue Growth YoY(%)
60.2%16.0%80.3%129.6%
Constant-Currency Revenue Growth YoY(%)
60.2%16.0%80.4%129.2%
Foreign Exchange & Hedging Impact (pp)(%)
0.0%0.0%-0.1%0.4%
Contract Manufacturing, Royalty & Other Revenue($M)3
15024224743.8151245293130232109182118
Reported Revenue Growth YoY(%)
-1.0%-0.9%-15.8%-66.2%-34.7%124.4%61.3%11.6%-17.8%-31.7%-38.5%-38.4%
Constant-Currency Revenue Growth YoY(%)
-1.1%-4.5%-20.4%-65.7%-35.2%119.2%62.7%9.1%-18.8%-31.6%-39.5%-38.3%
Foreign Exchange & Hedging Impact (pp)(%)
0.1%3.6%4.6%-0.5%0.5%5.2%-1.4%2.5%1.0%-0.1%1.0%-0.1%
LEQEMBI Global In-Market Sales (Recorded by Eisai)($M)1
20218416813412116096876740197
LEQEMBI U.S. In-Market Sales($M)
107978678696352503930
LEQEMBI Global Pre-Audit Revenue (Eisai Official, JPY B)(M)3
32.229.326.220.71823.114.7106.302.83
United States (JPY B)(M)
17.115.413.411.910.29.10
Japan (JPY B)(M)
6.906.106.506.206.205.50
China (JPY B)(M)
4.904.804.100.400.207.70
Biogen 50% Alzheimer's Collaboration Net Revenue($M)3
68.463.759.547.142.754.93326.718.611.82.801.60
LEQEMBI Collaboration SG&A Expense Incurred($M)
168155170176177171178171165138174113
Accounts Receivable from Collaborator — Eisai($M)
14.3134790.210414311616.793.210.315.91.40
Accounts Payable to Collaborator — Eisai($M)
46.792.585.495.597.997.5123138146172181118
Rare Disease Product Revenue($M)3
676602557515533543563535495534424472
Reported Revenue Growth YoY(%)
26.8%10.8%-1.1%-3.9%7.8%1.7%32.9%13.5%10.0%-1.8%-35.0%-15.5%
Constant-Currency Revenue Growth YoY(%)
26.9%8.8%-4.9%-3.6%6.1%2.8%35.6%14.8%9.9%0.5%-35.0%-11.6%
Foreign Exchange & Hedging Impact (pp)(%)
-0.1%2.0%3.8%-0.3%1.7%-1.1%-2.7%-1.3%0.1%-2.3%0.0%-3.9%
Other Product Revenue (Postpartum Depression & Legacy)($M)3
84.470.855.465.755.346.829.425.624.117.615.24
Reported Revenue Growth YoY(%)
52.6%51.4%88.4%128.9%169.5%93.4%
Constant-Currency Revenue Growth YoY(%)
52.6%51.4%87.4%129.7%170.4%92.3%
Foreign Exchange & Hedging Impact (pp)(%)
0.0%0.0%1.0%-0.8%-0.9%1.1%
Multiple Sclerosis (MS) Product Revenue($M)3
9199639589171,0621,1079531,0701,0541,1501,0761,168
Reported Revenue Growth YoY(%)
-13.4%-13.0%0.5%-14.3%0.7%-3.7%-11.4%-8.4%-9.1%13.4%-4.4%-7.9%
Constant-Currency Revenue Growth YoY(%)
-13.3%-14.4%-2.9%-15.1%-0.4%-3.9%-10.4%-9.1%-9.2%13.5%-4.2%-6.4%
Foreign Exchange & Hedging Impact (pp)(%)
-0.1%1.4%3.4%0.8%1.1%0.2%-1.0%0.7%0.1%-0.1%-0.2%-1.5%
Biosimilars Product Revenue($M)3
166153182170197182181202197198197188
Reported Revenue Growth YoY(%)
-15.7%-15.9%0.8%-15.7%0.1%-8.3%-8.2%7.1%1.2%1.5%538.4%94.7%
Constant-Currency Revenue Growth YoY(%)
-19.2%-20.0%-6.5%-15.1%-0.3%-7.6%-4.9%4.1%0.2%1.0%541.6%90.0%
Foreign Exchange & Hedging Impact (pp)(%)
3.5%4.1%7.3%-0.6%0.4%-0.7%-3.3%3.0%1.0%0.5%-3.2%4.7%
SYFOVRE (Geographic Atrophy) — Continuous Full-Quarter U.S. Net Revenue($M)
191162151155151151130168152155138114
EMPAVELI (PNH / C3G / IC-MPGN) — Continuous Full-Quarter U.S. Net Revenue($M)
51.54641.335.126.820.819.723.424.624.525.624.4
Apellis Standalone Total Revenue (Pre-Acquisition through Q1 2026)($M)3
268200459179167213197200172146
SYFOVRE Pre-Acquisition Net Product Revenue($M)
151155151151130168152155138114
EMPAVELI Pre-Acquisition Net Product Revenue($M)
41.335.126.820.819.723.424.624.525.624.4
Apellis Ending GTN Product Revenue Reserves($M)
65.858.647.544.538.945.132.922.719.216.6
Apellis Standalone Operating Expenses (Pre-Acquisition)($M)7
242251235212250239244229234231
Apellis Standalone R&D Expense($M)
7774.268.26786.476.388.67884.769.3
Apellis Standalone SG&A Expense($M)
124147143131129122122128130142
Apellis Standalone Operating Income / (Loss)($M)
26.5-51.1223-33.3-83.3-26.2-47.3-29.4-62.1-84.5
Apellis Standalone Net Income / (Loss)($M)
18.7-59216-42.1-92.2-36.4-57.5-37.7-66.4-88.6
Apellis Standalone Operating Cash Flow($M)
-61-14.21094.40-53.419.434.1-8.30-133-97.9
Apellis Standalone Cash & Equivalents($M)
405466479370358411397360326351
Apellis Standalone Net Inventories($M)3
13114312312182.581.4121153161146
Raw Materials($M)
42.143.352.256.449.954.446.650.542.132.7
Work in Process($M)
10412110810183.792.911411710682.9
Finished Goods($M)
13.7134.1011.59.509.906.808.801330.7
Ending Gross-to-Net (GTN) Product Revenue Reserves($M)5
1,2911,2431,1771,2111,3221,2711,1701,0921,1511,1161,0971,062
Contractual Adjustments (Managed Care, Medicaid, Medicare & Chargebacks)($M)
1,0971,0671,0201,0461,1011,035950881923910903857
Cash Discounts Reserve($M)
131122105116163176167163186162158173
Product Returns & Allowances Reserve($M)
62.854.551.74957.860.353.848.142.543.536.431.6
Recorded as Deduction from Accounts Receivable($M)
271263216210260274205154151152140136
Recorded in Accrued Expense & Other Current Liabilities($M)
1,0209809611,0001,0629979659381,000965957927
GTN Provisions Related to Sales in Current Year($M)4
975900905957870930881910860896869923
Contractual Adjustments Provision($M)
739668684721651712690683650673683737
Cash Discounts Provision($M)
226226214225213208186219206218182182
Product Returns Provision($M)
9.606.107.3011.25.809.305.60855.6054.80
GTN Adjustments Related to Prior-Year Sales($M)
11.540.317.21.3020.232.926.13.603.903.805.2015.2
GTN Payments & Credits Applied — Current-Year Sales($M)4
826672389867734687348830773687371745
Contractual Adjustments Paid (Current-Year Sales)($M)
614490255635527515230599593536262583
Cash Discounts Applied (Current-Year Sales)($M)
213183133231207172118231180151109163
Product Returns Applied (Current-Year Sales)($M)
-0.2000.101.200.300.100.100.200.100.100.200.10
GTN Payments & Credits Applied — Prior-Year Sales($M)3
89.417353320064.211042813648.4186458173
Contractual Adjustments Paid (Prior-Year Sales)($M)
81.612442613938.880.936012137.1119358163
Cash Discounts Applied (Prior-Year Sales)($M)
3.7036.792.341.819.726.964.911.1561.694.25.30
Product Returns Applied (Prior-Year Sales)($M)
4.101314.918.55.702.103.703.306.305.505.604.80
Largest Wholesale Distributor — Share of Gross Product Revenue(%)1
30.3%29.9%27.3%27.8%28.2%25.9%25.9%25.4%25.6%
Second-Largest Wholesale Distributor — Share of Gross Product Revenue(%)
16.9%16.5%14.7%16.0%15.8%14.1%14.8%12.3%11.7%
R&D Expense Excluding Acquired IPR&D (Disaggregated by Stage)($M)5
574530539509436399434513516505445554
Late-Stage Clinical Programs (Phase 3 / Registrational)($M)
17612010377.660.444.649.474.156.346.732.6
Early-Stage Clinical Programs (Phase 1 & Phase 2)($M)
87.149.36973.559.951.972.471.864.166.684.1
Marketed Products Post-Approval R&D($M)
11315215412810887.789.5121126170118
Research & Discovery Programs($M)
54.241.640.551.34146.644.359.948.345.747.6
Other R&D Costs & Infrastructure Overhead($M)
144167173179167168179187222176163
Total R&D Including Acquired IPR&D, Upfront & Milestones($M)2
284164342.1046.620126.58.507.50
Cash Payments to Acquire In-Process R&D($M)
2251003550000
Discovery & Preclinical Collaboration R&D Expense($M)
51.3434-62.1016.6111.526.58.507.501.30
Collaboration Profit Sharing / (Loss Reimbursement), Net Expense($M)9
77.868.874.269.987.27558.157.169.362.465.654.3
Samsung Bioepis Biosimilars Profit Sharing($M)
4944.957.247.566.557.24850.660.355.960.653.1
ZURZUVAE U.S. 50/50 Collaboration Profit Sharing (Sage / Supernus)($M)
28.823.91722.420.717.810.16.5096.505-1.20
ZURZUVAE Collaboration R&D Expense Incurred($M)
11.201.200.50-1.701.502.404.608.409.6011.617.8
ZURZUVAE Collaboration SG&A Expense Incurred($M)
56.453.347.54241.845.743.535.628.426.927.634.7
Denali Therapeutics Collaboration R&D Expense Incurred($M)
2.305.5010.37.8011.412.112.88.6014.915.414.213.7
Stoke Therapeutics (Zorevunersen) Collaboration R&D Incurred($M)
28.614.312.239.49.108.903.90
UCB (Dapirolizumab Pegol) Collaboration R&D Incurred($M)
38.429.329.417.123.217.821.825.219.216.516.6
Accrued Royalties Payable (Current)($M)
348338309302320200167190179193162192
Accrued Collaboration Expenses (Current)($M)
234199354280269180233309281319278215
Non-GAAP Net Income Attributable to Biogen Inc.($M)
391536529294708803443502596771535430
Non-GAAP Diluted Earnings Per Share($)1
2.623.603.571.994.815.473.023.444.085.283.672.95
Net Non-GAAP Adjustments per Diluted Share($)
2.762.941.422.321.641.141.381.611.421.280.971.24
Non-GAAP Cost of Sales (Excl. Acquired Intangible Amortization)($M)1
553612610510554580593504500587
Acquisition Inventory Fair Value Step-Up Amortization (COGS)($M)
19516449.70049.446.142.342.2
Non-GAAP Research & Development Expense($M)
567490480432394427491464447568
Non-GAAP Selling, General & Administrative Expense($M)
730680600592579572556542569588
Non-GAAP Amortization & Impairment of Acquired Intangibles($M)1
12.614.613.413.912.810.511.810.89.509.40
GAAP Acquired Intangible Amortization Excluded from Non-GAAP($M)
16015412312211510198.376.168.867.2
Non-GAAP Other Expense, Net($M)
91.460.14243.656.632.853.954.66362.3
Non-GAAP Income Tax Expense($M)2
97.911195.31471251079514610187.9
Non-GAAP Effective Tax Rate(%)
20.0%17.2%15.3%10.1%17.2%13.5%19.4%12.2%13.8%15.9%15.9%17.0%
GAAP Effective Tax Rate(%)
-128.5%26.4%15.4%12.8%16.3%14.7%22.7%8.5%13.9%16.5%15.4%14.7%
Non-GAAP Free Cash Flow($M)
6004085944681,226134222722901592507-52.7
Contingent Consideration Liabilities — Total Level 3 Fair Value($M)3
2702692672463915355225135090
Contingent Consideration Liabilities — Noncurrent($M)
122274267246243238228222222
Contingent Consideration Fair Value Remeasurement Loss / (Gain)($M)
0.402.5020.55.6013.29.6023.800
Level 3 Valuation — Weighted-Average Discount Rate(%)
6.9%5.9%5.7%5.4%5.4%5.7%5.9%6.2%5.6%
Total Restructuring Charges($M)3
66.51657.906.607.40-0.7035.35.306.806.6011.598.8
Workforce Reduction Severance Charges($M)
66.51657.907.40-0.7035.3
Workforce Reduction Restructuring Reserve Balance($M)
66.835.913.615.819.229.240.431.975.4
Workforce Reduction Restructuring Cash Payments($M)
35.814310.317.49.5025.8
Litigation Settlement & Loss Contingency Charges($M)
30.8-0.404.701310.805.2033.90
Inventories, Net (Current)($M)5
2,2242,3841,9492,1682,2092,2742,2742,4612,4692,5062,5172,527
Raw Materials($M)
321308279293296305306318369401413427
Work in Process (WIP)($M)
1,5381,6551,3521,5951,6351,6421,7171,8831,8041,8211,8511,927
Finished Goods($M)
499557458425441478368354391395348255
Long-Term Inventories (Included in Other Noncurrent Assets)($M)
13313614014516215111793.994.511194.981.7
Inventory Excess & Obsolescence Write-Downs($M)
9.305.104.8015.3-0.4077.3033.224.316.927.562.3
Finite-Lived Acquired Intangible Assets, Net($M)10
11,54911,7167,2557,3807,5297,6647,7787,8847,9598,0298,0815,859
Finite-Lived Intangible Assets, Gross($M)
18,71418,70914,07914,06714,08714,08714,10414,13814,10214,06414,02911,729
Finite-Lived Intangible Accumulated Amortization($M)
7,1656,9926,8246,6886,5596,4236,3266,2546,1436,0355,9485,870
Indefinite-Lived In-Process R&D (IPR&D) Assets($M)
1,6671,6361,6351,6351,6391,6391,6431,6431,68340402,340
Indefinite-Lived Trademarks & Trade Names($M)
646464646464646464646464
Priority Review Vouchers (Indefinite-Lived)($M)
100100100100100100100100100100100100
Estimated Intangible Amortization — Year 1 / Next 12M($M)
660665485485485565560525510565565345
Estimated Intangible Amortization — Year 2($M)
720735525485490600600560550660660470
Estimated Intangible Amortization — Year 3($M)
830815575525525630630600585680685485
Estimated Intangible Amortization — Year 4($M)
940925650575580665665630615710710480
Estimated Intangible Amortization — Year 5($M)
1,0451,025700645650700700665655720715495
Long-Term Debt Principal Maturities — After Year 51
Common Shares Held in Treasury (Millions)(M)
-23.8-23.8-23.8-23.8-23.8-23.8-23.8-23.8-23.8-23.8-23.823.8
U.S. Personal Consumption Expenditures: Health Care (SAAR, $B)(M)
3,8593,7903,7003,6673,6153,5303,4653,4183,3583,2883,2443,159
Total Revenue (GAAP)($M)14
2,8042,7362,4782,2792,5352,6462,4312,4552,4662,4652,2912,386
Cost of Sales (Excl. Acquired Intangible Amortization)($M)
748777661496674605629584639546542618
Research & Development Expense($M)
574530539509436399434513516505445554
Selling, General & Administrative Expense($M)
752710607683595584573680588554582609
Restructuring Charges($M)
66.51657.906.607.40-0.7035.35.306.806.6011.598.8
Total Cost & Expenses($M)
2,8132,6042,1002,3351,9771,9022,1202,1632,0151,7661,8262,095
Interest Income($M)
9.3025.337.937.231.632.323.918.511.620.117.423.8
Interest Expense($M)
87.582.367.667.567.472.6606059.861.369.271.5
Income Before Income Taxes($M)
-9132378-56557744311292451699465292
Income Tax Expense / (Benefit)($M)
11.634.958.2-7.1090.810970.724.862.511571.442.7
Net Income / (Loss) Attributable to Biogen Inc.($M)
-20.697.5320-48.9467635241267389584393250
Diluted Earnings / (Loss) Per Share (GAAP)($)
-0.140.662.153.174.331.642.6642.70
Basic Earnings / (Loss) Per Share (GAAP)($)
-0.140.662.173.184.331.652.674.012.71
Weighted-Average Diluted Shares(M)
148149148147147147146146146
Weighted-Average Basic Shares(M)
148148147147147146146146145
Total Assets($M)12
32,05432,08729,48329,44029,20828,33028,03328,04928,31326,80426,56826,845
Cash & Cash Equivalents($M)
1,3041,2853,3833,0093,8632,7592,5982,3751,6991,9091,0741,050
Inventories, Net($M)
2,2242,3841,9492,1682,2092,2742,2742,4612,4692,5062,5172,527
Total Current Assets($M)
7,5847,3069,1908,9748,9377,9687,6267,4576,8317,1096,7566,859
Property, Plant & Equipment, Net($M)
2,9682,9943,0183,0553,0763,0993,1323,1813,2113,2493,2753,310
Operating Lease Right-of-Use Assets($M)
176246251265331335346356380389428420
Goodwill($M)
6,9936,9916,4896,4916,4916,4936,4776,4796,4866,2276,2276,219
Acquired Intangible Assets, Net($M)
13,38013,5169,0549,1799,3329,4689,5859,6919,8068,2338,2858,363
Total Current Liabilities($M)
3,8983,9172,9993,3493,2903,1845,2975,5295,4253,1083,2233,434
Total Liabilities($M)
13,13213,23910,83111,18311,00010,69611,05411,33311,95410,91511,35512,045
Retained Earnings($M)
20,94920,97020,87220,55320,60220,13519,50019,26018,99318,60518,02117,628
Treasury Stock, at Cost($M)
-2,977-2,977-2,977-2,977-2,977-2,977-2,977-2,977-2,977-2,977-2,977-2,977
Total Stockholders' Equity($M)
18,92218,84818,65218,25718,20817,63416,97916,71616,35915,88915,21314,799
Net Cash Flow from Operating Activities($M)5
6414496465121,27316125976193662655312.5
Depreciation & Amortization($M)
241236204200202194183184183159148140
Share-Based Compensation Expense($M)
81.577.48459.675.374.98175.1-75-72.972.854.9
Capital Expenditures (Purchases of PP&E)($M)
40.440.951.243.946.226.637.139.33533.545.965.2
Net Cash Flow from Investing Activities($M)
-222-3,839-210-1,232-35.1-57-47.3-18.6-1,181467-66-652
Net Cash Flow from Financing Activities($M)
-3941,296-43.8-137-130-11.7-237.90-6.60-245-440-646

25 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar & segment structure: Biogen Inc. reports on a calendar fiscal year ending December 31 (latest quarter: Q3 2026 ended September 30, 2026; latest annual filing: FY2025 ended December 31, 2025). Because Biogen operates as a single global biopharmaceutical reportable segment, commercial performance is tracked across therapeutic franchises (Rare Disease, Multiple Sclerosis, Specialized Immunology, Biosimilars, Other), individual medicines split by U.S. and Rest of World, Anti-CD20 royalties/profit share, and the 50/50 Eisai Alzheimer's collaboration.
  • LEQEMBI in-market vs. GAAP collaboration accounting (Group 2): Lead collaboration partner Eisai Co., Ltd. books global commercial product sales of LEQEMBI ($202.0M global and $107.0M U.S. in Q3 2026; JPY 32.2B global across U.S. JPY 17.1B, Japan JPY 6.9B, and China JPY 4.9B in Jul–Sep 2026), whereas Biogen's GAAP income statement records only Biogen's 50% net share of revenue less cost of sales and royalties ($68.4M in Q3 2026).
  • Acquisition of Apellis Pharmaceuticals, Inc. (Group 5): On May 14, 2026, Biogen completed the $5.3B acquisition of Apellis Pharmaceuticals, Inc. (CIK 0001492422), adding SYFOVRE (geographic atrophy) and EMPAVELI (PNH, C3G, primary IC-MPGN) as the new Specialized Immunology franchise. Group 5 presents both Apellis's standalone pre-merger SEC disclosures through Q1 2026 and the unbroken full-quarter U.S. net revenue trajectory bridging Q2 2026 ($162.0M full quarter vs. $97.4M post-close in Biogen GAAP for SYFOVRE; $46.0M full quarter vs. $30.4M post-close for EMPAVELI) into Q3 2026 ($191.3M and $51.5M).
  • Methodology & calculations: No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. Every cell reflects published figures (with verbatim excerpts shown on hover for text-extracted metrics); the only arithmetic applied in table cells is period splitting from cumulative year-to-date filings (Q4 = full year − 9M; quarter = YTD − prior YTD), shown in italic with the formula.

Không hiện vì thiếu các kỳ gần đây (7)

  • Contingent Consideration, Fit for Growth Restructuring & Litigation › Contingent Consideration Liabilities — Total Level 3 Fair Value › Contingent Consideration Liabilities — Current — fewer than 3 consecutive latest periods
  • Contingent Consideration, Fit for Growth Restructuring & Litigation › Total Restructuring Charges › Fit for Growth Cumulative Positions Eliminated Target — fewer than 3 consecutive latest periods
  • Consolidated Financial Statements (GAAP Reference) › Total Revenue (GAAP) › Gross Profit — fewer than 3 consecutive latest periods
  • SYFOVRE commercial & free-goods doses delivered (Apellis pre-merger Form 8-K updates) — Discontinued after Q4 2025; post-acquisition Biogen reports YoY commercial injection volume growth % rather than absolute dose shipments.
  • SYFOVRE commercial injection volume growth YoY % (+13% in Q2 2026; +18% in Q3 2026) — Only 2 consecutive post-acquisition quarters published through Q3 2026 (minimum 3 required).
  • Cumulative patients treated worldwide ('more than 2 million patients from 1996 through 2025', SASB HC-BP-000.A) — Excluded because only disclosed as an open-ended bound ('more than').
  • Point-in-time SPINRAZA high-dose conversion rate ('70% of 12 mg patients with start forms submitted and 50% dosed', Q3 2026 call) — Single-quarter launch commentary without a 3-quarter continuous series.

Dữ liệu cập nhật 2026-11-10.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Biogen

See a number that looks wrong?